These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11501935)

  • 1. Application of high-performance, thin-layer chromatography to quality control of antimetabolite analogue infusion bags.
    Perello L; Demirdjian S; Dory A; Bourget P
    J AOAC Int; 2001; 84(4):1296-300. PubMed ID: 11501935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial growth tests in anti-neoplastic injectable solutions.
    Paris I; Paci A; Rey JB; Bourget P
    J Oncol Pharm Pract; 2005 Mar; 11(1):7-12. PubMed ID: 16460598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compatibility study of 5-fluorouracil with PVC bags after repackaging into two types of infusion admixtures.
    Benaji B; Faouzi MA; Dine T; Goudaliez F; Luyckx M; Brunet C; Kablan J; Gressier B; Cazin M; Cazin JC
    Therapie; 1999; 54(5):659-63. PubMed ID: 10667105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
    Wilke H; Stahl M; Köster W; Vanhöfer U
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():3-8. PubMed ID: 10941246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
    J Natl Cancer Inst; 1997 Apr; 89(7):497-505. PubMed ID: 9086006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of high-performance thin-layer chromatography to a pharmaceutical quality assurance programme in a hospital chemotherapy manufacturing unit.
    Bourget P; Paci A; Rey JB; Mercier L; Demirdjian S
    Eur J Pharm Biopharm; 2003 Nov; 56(3):445-51. PubMed ID: 14602189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
    Gravel E; Bourget P; Mercier L; Paci A
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):581-6. PubMed ID: 16023817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ion-pairing, reversed-phase liquid chromatography method to assess the cross-contamination of cancer chemotherapy infusions prepared in a dual-operator aseptic isolator.
    Brachet G; Bruno C; Boulay D; Tournamille JF; Gyan E; Viaud-Massuard MC; Respaud R
    Drug Test Anal; 2016 Sep; 8(9):985-90. PubMed ID: 26480955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvement of quality of practices for the preparation of cytotoxic drugs: results of a "before-after" study].
    Gilles L; Favier B; Catillon F; Dussart C; Peyron F; Simoens X; Latour JF; Farsi F; Biron P
    Bull Cancer; 2009 Sep; 96(9):839-49. PubMed ID: 19696008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
    Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
    J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusional 5-FU: historical evolution, rationale, and clinical experience.
    Lokich J
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):19-22. PubMed ID: 9830620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [5-fluorouracil].
    Aiba K
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1368-79. PubMed ID: 11681244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
    Arkenau HT; Rettig K; Porschen R
    Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ Analytical Quality Control of chemotherapeutic solutions in infusion bags by Raman spectroscopy.
    Makki AA; Elderderi S; Massot V; Respaud R; Byrne HJ; Tauber C; Bertrand D; Mohammed E; Chourpa I; Bonnier F
    Talanta; 2021 Jun; 228():122137. PubMed ID: 33773705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
    Shaib W; Lee V; Saif MW
    In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
    Hrovatin E; Viel E; Lestuzzi C; Tartuferi L; Zardo F; Brieda M; Dametto E; Piazza R; Antonini-Canterin F; Vaccher E; Meneguzzo N; Nicolosi GL
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):637-40. PubMed ID: 16858245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
    Nitti D; Wils J; Sahmoud T; Curran D; Couvreur ML; Lise M; Rauschecker H; dos Santos JG; Stremmel W; Roelofsen F
    Eur J Cancer; 1997 Jul; 33(8):1209-15. PubMed ID: 9301444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.